IRCT20140126016374N2
Completed
Phase 3
The study of of Escitalopram ?s effectiveness on treatment of mild to moderate depressive disorder and improvement of quality of life in patients who are undergone coronary artery bypass graft surgery (CABG) – A randomized double blind placebo controlled trial
niversity of social welfare and rehabilitation sciences0 sites50 target enrollmentTBD
Overview
- Phase
- Phase 3
- Intervention
- Not specified
- Conditions
- Not specified
- Sponsor
- niversity of social welfare and rehabilitation sciences
- Enrollment
- 50
- Status
- Completed
- Last Updated
- 4 years ago
Overview
Brief Summary
No summary available.
Investigators
Eligibility Criteria
Inclusion Criteria
- •coronary artery bypass graft surgery
- •Age \>18 (18\-75\)
- •patient with beck depression inventory score 10\-20
Exclusion Criteria
- •Previous history of intolerance to serotonin reuptake inhibitor antidepressants
- •Psychosis or dementia or mental retardation disorder in the patient
- •Severe liver disease
- •High risk of postoperative cardiac complications such as bleeding
- •Patients participating in other trials
- •History of bipolar disorder
- •Patients who have been treated with escitalopram or an antidepressant during the previous month
- •Recent abuse of alcohol and substances
- •Pregnancy and lactation
Outcomes
Primary Outcomes
Not specified
Similar Trials
Recruiting
Not Applicable
escitalopram in depressive patients with acute coronary artery syndromeMental and behavioral disordersKCT0000053Chonnam National University Hospital300
Recruiting
Phase 3
Treatment of depressive symptoms in patients with heart failureDepression.Major depressive disorder, single episode, mildF32.0IRCT20190525043700N5Babol University of Medical Sciences80
Completed
Phase 3
The effect of treatment with escitalopram on quality of life and hospitalization rate in depressed patients with systolic heart failureheart failure.Heart failureIRCT20230510058142N1Shahid Beheshti University of Medical Sciences84
Completed
Phase 4
Comparison Of Two Anti Depressant Drugs In Major Depressive DisorderHealth Condition 1: null- Major Depressive DisorderCTRI/2018/02/011662Government Medical College50
Active, not recruiting
Phase 1
A Randomised Controlled Trial of Escitalopram and Nortriptyline compared with placebo, and standard psychological care, for depression in Parkinson’s diseaseDepression in Parkinson's diseaseMedDRA version: 20.0Level: PTClassification code 10012378Term: DepressionSystem Organ Class: 10037175 - Psychiatric disordersMedDRA version: 20.0Level: PTClassification code 10061536Term: Parkinson's diseaseSystem Organ Class: 10029205 - Nervous system disordersTherapeutic area: Diseases [C] - Nervous System Diseases [C10]EUCTR2018-002942-35-GBniversity College London Comprehensive Clinical Trials Unit408